药学本科毕业论文.doc

药学本科毕业论文77685沈阳药科大学本科毕业论文论文题目:化合物A联合化合物B对人肝癌HepG2细胞作用机制研究起止时间:2014年10月26日—2015年6月20日姓名学号:学院专业:年级班级:指导教师:XXX副教授实****单位:XXX大学生命科学与生物制药学院药理系目录中文摘要······································································1英文摘要······································································2第1章绪论····························································································································································································5第2章实验部分····················································································································································································································································12第3章结论与讨论···························································································································································································18参考文献·····································································21致谢·········································································23摘要原发性肝癌是世界常见的恶性肿瘤之一,也是我国的高发恶性肿瘤,由于不易被早期诊断,进展迅速,术后容易复发、转移,因此预后较差。目前肝癌仍以外科手术为公认首选和主要的治疗手段,但由于很多肝癌患者确诊时已是中晚期,失去了手术治疗的机会并于诊断后1年内死亡,手术切除率<30%,术后总体5年生存率仅30%~40%。对于可手术的肝癌患者,术后复发、转移是影响治疗效果及预后的主要因素,对于不能手术的中晚期肝癌患者尚缺乏有效的治疗方法。传统的化疗、放疗对肝癌疗效欠佳,目前仍缺乏行之有效的化学预防和治疗靶位[1]。因而本课题是对化合物A联合化合物B对人肝癌HepG2细胞作用机制研究。本实验首先用MTT法分别测得不同浓度的A和B单独处理HepG2细胞及不同浓度的A和B联合用药处理HepG2细胞死亡的影响。结果表明不同浓度的A和B单独处理HepG2细胞,增值抑制程度表现为时间剂量依赖效应,并且在A6μmol/L联合B100μmol/L协同作用最为显著。流式细胞仪检测细胞凋亡率显示,联合用药组凋亡率升高更为明显。WesternBlot法检测蛋白显示,促凋亡相关蛋白Bax、FADD增加,抗凋亡蛋白Bcl-2表达减少。关键词联合用药,细胞凋亡,作用机制AbstractHepatocellularcarcinoma(HCC),rapidlyprogressesanddelayeddiagnosis,thismalignancyhasagrimprognosisevenfollowingsurgicalresectionandhashighdisease-recurrence..Unfortunately,thediseaseisusuallydetectedatanadvancedstage,andthemajorpatientslosethecha